Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Erasmus Medical Center

Reviewed by TrialFinderData Editorial Team · Updated

9 clinical trials · 9 recruiting · OTHER

Erasmus Medical Center has 9 clinical trials registered on ClinicalTrials.gov, with 9 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Erasmus Medical Center\'s Trial Portfolio

Erasmus Medical Center is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

9 of Erasmus Medical Center's 9 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Erasmus Medical Center's research footprint spans acromegaly-due-to-pituitary-adenoma (1 trials), ketogenic-diet (1), and Mediterranean Diet (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in Erasmus Medical Center's portfolio at 33% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Erasmus Medical Center

RECRUITINGNCT06949891

KETOgenic Diet Therapy in Patients With ACROmegaly

Acromegaly is caused by a tumour located at the base of the brain in the pituitary gland that produces too much growth hormone (GH). Symptoms caused by the excess of GH, and...

Sponsor: Erasmus Medical CenterEnrolling: 601 location
Acromegaly Due to Pituitary AdenomaKetogenic DietMediterranean Diet
RECRUITINGNCT06601231

To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC...

The goal of this prospective observational study is to test the impact of addition of the GAAD score to imaging in patients with chronic liver disease eligible for HCC...

Sponsor: Erasmus Medical CenterEnrolling: 10001 location
Cancer, Hepatocellular
RECRUITINGNCT06026189

Safely Reduce Cystoscopic Evaluations for Hematuria Patients

The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.

Sponsor: Erasmus Medical CenterEnrolling: 11001 location
HematuriaUrothelial NeoplasmUrothelial Carcinoma+1
RECRUITINGNCT07114627

Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients

In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form. In the body,...

Sponsor: Erasmus Medical CenterEnrolling: 661 location
Solid CancerGastric (Cardia, Body) CancerEsophageal Cancer+1
RECRUITINGNCT06720636

Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy

The purpose of this study is to evaluate the Endosign capsule sponge test as a novel surveillance method in patients with an ultralong-segment Barrett's esophagus.

Sponsor: Erasmus Medical CenterEnrolling: 1371 location
Barrett Esophagus
RECRUITINGPhase 1NCT05304208

dENdritic Cell Therapy Combined With SURgEry in Mesothelioma

The ENSURE trial is an open label, single center, phase 1, feasibility study. Sixteen adult patients diagnosed with resectable epithelioid malignant pleural mesothelioma (MPM)...

Sponsor: Erasmus Medical CenterEnrolling: 161 location
Mesotheliomas Pleural
RECRUITINGPhase 4NCT05552287

Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease

Rationale: Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients. The use of anti-tumor...

Sponsor: Erasmus Medical CenterEnrolling: 501 location
Crohn DiseaseChild, OnlyBiologic; Inadequate
RECRUITINGNCT04304898

An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology

The I-FILE study is a prospective multicenter, multinational observational study where the feasibility of a patient-led registry using home monitoring in patients with pulmonary...

Sponsor: Erasmus Medical CenterEnrolling: 7002 locations
Pulmonary Fibrosis
RECRUITINGPhase 4NCT06766461

Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis

The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.

Sponsor: Erasmus Medical CenterEnrolling: 9801 location
Sepsis - to Reduce Mortality in the Intensive Care UnitSepsisSeptic Shock

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Erasmus Medical Center have on ClinicalTrials.gov?

Erasmus Medical Center has 9 clinical trials registered on the federal ClinicalTrials.gov registry, of which 9 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Erasmus Medical Center study?

Erasmus Medical Center's registered trials cover 20 conditions on ClinicalTrials.gov, led by acromegaly-due-to-pituitary-adenoma (1 trial), ketogenic-diet (1 trial), Mediterranean Diet (1 trial), cancer-hepatocellular (1 trial), Hematuria (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Erasmus Medical Center clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 9 trials tracked for Erasmus Medical Center.